• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Primary Care

Cellulitis: Clinical Presentation, Differential Diagnosis and Treatment

image_pdfFavoriteLoadingFavorite

Summary:

Cellulitis is an infection of the soft tissue deep to the skin that results in erythema, inflammation, tenderness, and pain. It is most commonly caused by Streptococcus pyogenes or staphylococcus aureus. Other etiology bacteria include haemophilus influenza, streptococcus pneumonia, gram negative, and anaerobic species. The treatment is with antibiotics targeted at the suspected etiologic organism. Cephalexin is standard for non-purulent cellulitis, with coverage for methicillin-resistant staphylococcus aureus being necessary in the setting of purulence. Duration and intravenous (IV) versus oral anti- microbial therapy is dependent on the clinical severity

Microbiology

  • Beta-hemolytic streptococcus species
  • Staphylococcus aureus
    • Most common organism in abscesses with the exception or perioral or perirectal locations
    • Large burden of methicillin-resistance Staphylococcus aureus (MRSA)
  • Specific situations
    • Pasteurella multocida in the setting of animal bites
    • Aeromonas hydrophila and Vibro vulnificus in water exposure
    • Clostridium species in gas gangrene

Clinical Presentation

  • Presents as a local area of erythema(less obvious on hyperpigmented skin tones), warmth, tenderness, and pain
  • May be patchy
  • Typically unilateral
  • Lower extremities are the most common location
  • Skin should be inspected for areas of breakdown, including maceration
    • Other predisposing conditions include lymphedema, venous insufficiency, immunocompromise, tinea infections
Cellulitis of the right thigh. Image courtesy of dermnetnz.org
Cellulitis of the right leg. Image courtesy of dermnetnz.org

Risk Factors & Transmission

  • Any skin disruption, such as tinea, ulcers, or wounds
  • Prior cellulitis
  • Venous insufficiency or impaired lymphatic drainage
  • Chronic edema
  • Obesity
  • Injection drug use

Differential Diagnosis

  • Erysipelas | Has sharply demarcated and raised borders
  • Necrotizing fasciitis
  • Gas gangrene
  • Varicella zoster
  • Stasis dermatitis
    • Typically both lower legs unlike unilateral presentation in cellulitis
  • Septic arthritis or bursitis
    • Consider if located near a relevant structure
  • Gout
    • Consider if clearly inflamed joint or a prior history of similar symptoms
  • Insect bite
    • Some bites can be associated with large local reactions, e.g., Lyme disease (without typical ‘bullseye’ pattern)
    • Outdoor activity or unusual location for cellulitis may point to Lyme

Diagnosis

  • Clinical diagnosis suspected when there is an appropriate history and physical exam
  • Identify if any abscess is present either clinically or with ultrasound

Treatment

  • Incise and drain any detectible abscess  
  • Culture any abscess, although deferral is reasonable in a typical case
    • Skin cultures of non-purulent cellulitis are not recommended
  • Mark the leading edge of erythema

Antibiotic choice depends on location of care and suspected etiologic agent (see below)

  • Location of care
    • Admission is indicated for systemic signs, intractable pain, suspicion of deep space infection, immunocompromise, or failed outpatient treatment
    • Admission requires intravenous antibiotics and blood cultures are recommended
    • Transition to an appropriate oral agent may occur after clinical improvement
  • Etiologic agent
    • Purulent infections must consider agent active against MRSA
    • Perirectal, perioral, or pressure ulcers require MRSA, gram-negative, and anaerobic coverage pending culture results
    • If cellulitis associated with penetrating trauma or if evidence of MRSA infection elsewhere, nasal colonization with MRSA, injection drug use, or systemic inflammatory response syndrome; coverage against both MRSA and streptococci recommended
  • See below for antibiotic choices

Duration

  • Uncomplicated cellulitis: 5 days of therapy is sufficient if clinical improvement has occurred
  • Admitted patients: Up to 14 days may be required depending on clinical course

Antibiotics list

Purulent infection, with or without abscess (MRSA coverage needed)

  • Oral agents
    • Trimethoprim-Sulfamethoxazole 1-2 double-strength tablets BID
    • Doxycycline 100 mg BID
    • Clindamycin 300-450 mg QID
  • Intravenous agents
    • Vancomycin dosed per hospital protocol
    • Linezolid 600 mg every 12 hours
    • Daptomycin 4 mg/kg every 24 hours

Non-purulent infection (coverage for MRSA considered if risk factors)

  • Oral agents
    • Cephalexin 500 mg QID
    • Dicloxacillin 500 mg QID
    • Clindamycin 300-450 mg QID
    • Trimethoprim-Sulfamethoxazole 1-2 double-strength tablets BID
  • Intravenous agents
    • Cefazolin 1 g every 8 hours
    • Nafcillin or oxacillin 1 g every 8 hours
    • Clindamycin 600 mg every 8 hours

Learn More – Primary Sources

Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Disease Society of America

NICE Guideline: Cellulitis and erysipelas: antimicrobial prescribing (2019)

Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians (2021)

CDC: Cellulitis

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Primary Care Posts
Next >

Related ObG Topics:

ACP Guidelines: Best Practices for Use of Short-Duration Antibiotics for Common Infections
Herpes Zoster: Clinical Presentation and Treatment
Lyme Disease: Diagnosis and Treatment

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site